FDAsafety guidance72% confidence
Guidance Documents for Rare Disease Drug Development
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (rare disease) as Sanofi.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Cardiology · Fabry Disease
- Sub-indication
- Rare Disease
Related signal: Sanofi's Venglustat Phase 3 Trial Targets Left Ventricular Mass in Fabry Disease